See more : Changshu Tianyin Electromechanical Co.,Ltd (300342.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Madrigal Pharmaceuticals, Inc. (MDGL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Madrigal Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FSport AB (publ) (FSPORT.ST) Income Statement Analysis – Financial Results
- GiXo Ltd. (9219.T) Income Statement Analysis – Financial Results
- Shanghai Fudan Microelectronics Group Company Limited (1385.HK) Income Statement Analysis – Financial Results
- Lotus Eye Hospital and Institute Limited (LOTUSEYE.NS) Income Statement Analysis – Financial Results
- Liberty TripAdvisor Holdings, Inc. (LTRPB) Income Statement Analysis – Financial Results
Madrigal Pharmaceuticals, Inc. (MDGL)
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Cost of Revenue | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -527.00K | -467.00K | -405.00K | -471.00K | -112.00K | -96.00K | -77.00K | -156.00 | 0.00 | 0.00 | 0.00 | 147.00K | 7.58M | 14.80M | 144.25M | 2.62M | 743.00K | 0.00 | 0.00 | 173.00K | 1.30M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 271.82M | 245.44M | 205.16M | 184.81M | 72.32M | 25.39M | 24.39M | 15.93M | 54.22M | 68.21M | 71.86M | 49.41M | 41.46M | 40.25M | 51.05M | 81.58M | 52.03M | 50.50M | 59.90M | 38.14M | 24.34M | 7.29M | 277.00K |
| General & Administrative | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 15.29M | 7.67M | 9.29M | 13.39M | 15.75M | 15.70M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 11.28M | 7.38M | 5.26M | 0.00 | 124.00K |
| Other Expenses | 0.00 | 0.00 | 273.00K | 100.00K | 0.00 | 200.00K | 350.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Cost & Expenses | 380.50M | 293.57M | 242.48M | 206.67M | 94.97M | 40.68M | 32.06M | 25.22M | 67.61M | 83.95M | 87.56M | 61.09M | 53.02M | 51.70M | 63.71M | 96.32M | 66.96M | 59.15M | 71.18M | 45.52M | 29.60M | 7.29M | 401.00K |
| Interest Income | 19.58M | 2.19M | 363.00K | 4.33M | 11.02M | 7.67M | 558.00K | 48.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 12.71M | 3.96M | 0.00 | 0.00 | 11.02M | 7.67M | 558.00K | 1.16M | 1.06M | 2.21M | 2.63M | 1.85M | 1.95M | 569.00K | 312.00K | 489.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 527.00K | 467.00K | 405.00K | 471.00K | 112.00K | 96.00K | 77.00K | 156.00 | 662.00K | 673.00K | 516.00K | 738.00K | 1.46M | 1.93M | 2.46M | 2.72M | 3.35M | 3.66M | 2.46M | 1.55M | 1.01M | 47.06M | 0.00 |
| EBITDA | -379.97M | -293.10M | -242.08M | -206.20M | -94.86M | -40.59M | -31.99M | -22.52M | -3.23M | -83.28M | -87.04M | -60.20M | -43.97M | -34.97M | 81.86M | -90.99M | -62.87M | -53.62M | -71.04M | -43.80M | -27.29M | 10.80M | -401.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -40,954.42% | -579.75% | -236.20% | 58.40% | -3,479.58% | -8,827.19% | 0.00% | 0.00% | -24,977.46% | -2,124.54% | 0.00% | 0.00% |
| Operating Income | -380.50M | -293.57M | -242.48M | -206.67M | -94.97M | -40.68M | -32.06M | -25.22M | -67.61M | -83.95M | -87.56M | -60.94M | -45.43M | -36.90M | 79.30M | -93.71M | -66.22M | -59.15M | -71.18M | -46.93M | -28.29M | -36.26M | -401.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -41,456.46% | -599.05% | -249.26% | 54.98% | -3,583.48% | -8,911.98% | 0.00% | 0.00% | -27,126.59% | -2,169.79% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.87M | -1.78M | 636.00K | 4.43M | 11.02M | 7.87M | 908.00K | -1.16M | 60.77M | -2.21M | -2.63M | -1.85M | -1.95M | -569.00K | -216.00K | 1.09M | 2.72M | 22.00K | 2.32M | -588.00K | 416.00K | -18.09M | 0.00 |
| Income Before Tax | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -122.08M | -59.13M | -68.86M | -47.52M | -27.88M | -54.35M | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -16,430.69% | 0.00% | 0.00% | -27,466.47% | -2,137.88% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.96M | -768.00K | -4.80M | -11.14M | 7.87M | -635.00K | -373.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45M | 0.00 | -2.72M | -1.88M | -2.32M | 588.00K | -416.00K | -18.20M | 381.00K |
| Net Income | -373.63M | -299.31M | -241.08M | -197.44M | -72.81M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -63.50M | -57.27M | -68.86M | -45.93M | -27.88M | -36.15M | -381.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -42,714.29% | -624.74% | -253.10% | 54.83% | -3,541.80% | -8,545.76% | 0.00% | 0.00% | -26,551.45% | -2,137.88% | 0.00% | 0.00% |
| EPS | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.55 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| EPS Diluted | -19.99 | -17.47 | -14.58 | -12.78 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.20 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 | -105.09 | -4.55 |
| Weighted Avg Shares Out | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 968.21K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
| Weighted Avg Shares Out (Dil) | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.80M | 12.24M | 5.20M | 171.01K | 2.81M | 2.03M | 1.70M | 1.35M | 1.15M | 974.81K | 963.86K | 927.59K | 636.14K | 635.80K | 534.39K | 624.37K | 344.04K | 83.74K |
Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on...
3 Stocks That Could Be Monster Winners in 2024
CRISPR Therapeutics' innovative gene-editing therapy could be a game changer. Madrigal Pharmaceuticals hopes to soon win U.S. approval for a potential blockbuster NASH drug.
3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations
The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year,...
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to thirty-two new employees with a grant date of...
Huge Warren Buffett Purchase Highlights Hot Insider Buying
From executives to beneficial owners, insiders are increasingly stepping up to the buy window as we approach the end of the year.
See Which Inside Buyers Are Scooping Up More Shares Now
Some of the biggest insider purchases around and since the Thanksgiving holiday have come from repeat buyers.
These 2 Stocks Could Be About to Soar: Are They Buys?
Madrigal aims to offer a treatment in an area where success has eluded many peers. Bluebird Bio is closing in on its third U.S. approval for a gene-editing therapy.
Got $2,000? 3 Growth Stocks to Buy That Could Double Your Money
Madrigal Pharmaceuticals could soon launch its first drug. TransMedics Group is bringing much-needed disruption to the organ transplant market.
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to (i) Carole Huntsman, the Company's new Chief Commercial...
Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer
CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer.
Source: https://incomestatements.info
Category: Stock Reports